Anti-CD22 CAR (Cellular Biomedicine)

N/A

Report date: 2025/01/26 18:27:59

Base Information

Drug NameAnti-CD22 CAR (Cellular Biomedicine)
Drug Alias Nameanti-CD22 CAR T-cell therapy (Cellular Biomedicine)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionCD22 modulators
TargetsCD22
Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Hairy Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesAbelZeta Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbelZeta Inc
Inactive CompaniesN/A
Active IndicationsPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Hairy Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A